coenzyme-q10 and Syndrome

coenzyme-q10 has been researched along with Syndrome* in 11 studies

Reviews

3 review(s) available for coenzyme-q10 and Syndrome

ArticleYear
Nutritional Interventions in the Management of Fibromyalgia Syndrome.
    Nutrients, 2020, Aug-20, Volume: 12, Issue:9

    Fibromyalgia (FM) is a multifactorial syndrome of unknown etiology, characterized by widespread chronic pain and various somatic and psychological manifestations. The management of FM requires a multidisciplinary approach combining both pharmacological and nonpharmacological strategies. Among nonpharmacological strategies, growing evidence suggests a potential beneficial role for nutrition. This review summarizes the possible relationship between FM and nutrition, exploring the available evidence on the effect of dietary supplements and dietary interventions in these patients. Analysis of the literature has shown that the role of dietary supplements remains controversial, although clinical trials with vitamin D, magnesium, iron and probiotics' supplementation show promising results. With regard to dietary interventions, the administration of olive oil, the replacement diet with ancient grains, low-calorie diets, the low FODMAPs diet, the gluten-free diet, the monosodium glutamate and aspartame-free diet, vegetarian diets as well as the Mediterranean diet all appear to be effective in reducing the FM symptoms. These results may suggest that weight loss, together with the psychosomatic component of the disease, should be taken into account. Therefore, although dietary aspects appear to be a promising complementary approach to the treatment of FM, further research is needed to provide the most effective strategies for the management of FM.

    Topics: Acetylcarnitine; Ascorbic Acid; Chlorella; Diet, Vegan; Dietary Supplements; Fibromyalgia; Nutrition Therapy; Nutritional Physiological Phenomena; Syndrome; Ubiquinone; Vitamin E

2020
Clinical syndromes associated with Coenzyme Q
    Essays in biochemistry, 2018, 07-20, Volume: 62, Issue:3

    Primary Coenzyme Q deficiencies represent a group of rare conditions caused by mutations in one of the genes required in its biosynthetic pathway at the enzymatic or regulatory level. The associated clinical manifestations are highly heterogeneous and mainly affect central and peripheral nervous system, kidney, skeletal muscle and heart. Genotype-phenotype correlations are difficult to establish, mainly because of the reduced number of patients and the large variety of symptoms. In addition, mutations in the same

    Topics: Ataxia; Genotype; Humans; Mitochondrial Diseases; Muscle Weakness; Mutation; Phenotype; Structure-Activity Relationship; Syndrome; Ubiquinone

2018
[Coenzyme Q10 deficiency].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 4

    Topics: Coenzymes; Diagnosis, Differential; Humans; Lactic Acid; Mitochondria; Mitochondrial Diseases; Mitochondrial Encephalomyopathies; Myoglobinuria; Prognosis; Syndrome; Ubiquinone

2002

Trials

1 trial(s) available for coenzyme-q10 and Syndrome

ArticleYear
Therapeutic trial in the first three Asian cases of ethylmalonic encephalopathy: response to riboflavin.
    Journal of inherited metabolic disease, 2001, Volume: 24, Issue:8

    Three Korean girls with ethylmalonic encephalopathy, the first Asian cases, were identified. In all three cases, we observed slight improvement in motor functions, cognitive behaviours and chronic mucoid diarrhoea after treatment with riboflavin and/or coenzyme Q10 treatment. The precise pathogenesis of ethylmalonic encephalopathy has not been fully elucidated, but riboflavin treatment may be helpful.

    Topics: Brain Diseases, Metabolic, Inborn; Child, Preschool; Coenzymes; Cognition; Diarrhea; Electron Transport; Female; Humans; Infant; Korea; Malonates; Motor Skills; Riboflavin; Syndrome; Ubiquinone

2001

Other Studies

7 other study(ies) available for coenzyme-q10 and Syndrome

ArticleYear
Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study.
    BMC neurology, 2010, Jan-28, Volume: 10

    Cyclic vomiting syndrome (CVS), which is defined by recurrent stereotypical episodes of nausea and vomiting, is a relatively-common disabling condition that is associated with migraine headache and mitochondrial dysfunction. Co-enzyme Q10 (Co-Q) is a nutritional supplement that has demonstrated efficacy in pediatric and adult migraine. It is increasingly used in CVS despite the complete lack of studies to demonstrate its value in treatment. Using an Internet-based survey filled out by subjects with CVS or their parents, the efficacy, tolerability and subject satisfaction in CVS prophylaxis were queried. Subjects taking Co-Q (22 subjects) were compared against those taking amitriptyline (162 subjects), which is the general standard-of-care.. Subjects/parents reported similar levels of efficacy for a variety of episode parameters (frequency, duration, number of emesis, nausea severity). There was a 50% reduction in at least one of those four parameters in 72% of subjects treated with amitriptyline and 68% of subjects treated Co-Q. However, while no side effects were reported on Co-Q, 50% of subjects on amitriptyline reported side effects (P = 5 x 10-7), resulting in 21% discontinuing treatment (P = 0.007). Subjects/parents considered the benefits to outweigh the risks of treatment in 47% of cases on amitriptyline and 77% of cases on Co-Q (P = 0.008).. Our data suggest that the natural food supplement Co-Q is potentially efficacious and tolerable in the treatment of CVS, and should be considered as an option in CVS prophylaxis. Our data would likely be helpful in the design of a double-blind clinical trial.

    Topics: Age of Onset; Amitriptyline; Antiemetics; Humans; Internet; Parents; Patient Satisfaction; Periodicity; Retrospective Studies; Risk Assessment; Syndrome; Treatment Outcome; Ubiquinone; Vomiting

2010
Human CoQ10 deficiencies.
    BioFactors (Oxford, England), 2008, Volume: 32, Issue:1-4

    Coenzyme Q10 (CoQ10 or ubiquinone) is a lipid-soluble component of virtually all cell membranes and has multiple metabolic functions. A major function of CoQ10 is to transport electrons from complexes I and II to complex III in the respiratory chain which resides in the mitochondrial inner membrane. Deficiencies of CoQ10 (MIM 607426) have been associated with four major clinical phenotypes: 1) encephalomyopathy characterized by a triad of recurrent myoglobinuria, brain involvement, and ragged-red fibers; 2) infantile multisystemic disease typically with prominent nephropathy and encephalopathy; 3) cerebellar ataxia with marked cerebellar atrophy; and 4) pure myopathy. Primary CoQ10 deficiencies due to mutations in ubiquinone biosynthetic genes (COQ2, PDSS1, PDSS2, and ADCK3 [CABC1]) have been identified in patients with the infantile multisystemic and cerebellar ataxic phenotypes. In contrast, secondary CoQ10 deficiencies, due to mutations in genes not directly related to ubiquinone biosynthesis (APTX, ETFDH, and BRAF), have been identified in patients with cerebellar ataxia, pure myopathy, and cardiofaciocutaneous syndrome. In many patients with CoQ10 deficiencies, the causative molecular genetic defects remain unknown; therefore, it is likely that mutations in additional genes will be identified as causes of CoQ10 deficiencies.

    Topics: Cerebellar Ataxia; Humans; Mitochondrial Encephalomyopathies; Mitochondrial Myopathies; Syndrome; Ubiquinone

2008
Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes.
    Clinical biochemistry, 2008, Volume: 41, Issue:9

    To study CoQ(10) concentrations in muscle and fibroblast from 6 patients with a CoQ(10) deficiency syndrome.. CoQ(10) was quantified by HPLC with electrochemical detection.. Four out of the 6 cases showed muscle CoQ(10) deficiency plus a reduction of mitochondrial respiratory chain enzyme activities. All cases showed decreased CoQ(10) values in fibroblasts when compared with controls.. Biochemical study of CoQ(10) in both muscle and fibroblasts seems advisable to demonstrate the deficiency in all patients.

    Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Electron Transport; Fibroblasts; Humans; Infant; Infant, Newborn; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Syndrome; Ubiquinone

2008
Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency.
    Journal of inherited metabolic disease, 2007, Volume: 30, Issue:5

    The cardiofaciocutaneous (CFC) syndrome is characterized by congenital heart defect, developmental delay, peculiar facial appearance with bitemporal constriction, prominent forehead, downslanting palpebral fissures, curly sparse hair and abnormalities of the skin. CFC syndrome phenotypically overlaps with Noonan and Costello syndromes. Mutations of several genes (PTPN11, HRAS, KRAS, BRAF, MEK1 and MEK2), involved in the mitogen-activated protein kinase (MAPK) pathway, have been identified in CFC-Costello-Noonan patients. Coenzyme Q10 (CoQ10), a lipophilic molecule present in all cell membranes, functions as an electron carrier in the mitochondrial respiratory chain, where it transports electrons from complexes I and II to complex III. CoQ10 deficiency is a rare treatable mitochondrial disorder with various neurological (cerebellar ataxia, myopathy, epilepsy, mental retardation) and extraneurological (cardiomyopathy, nephropathy) signs that are responsive to CoQ10 supplementation. We report the case of a 4-year-old girl who presented a CFC syndrome, confirmed by the presence of a pathogenic R257Q BRAF gene mutation, together with a muscular CoQ10 deficiency. Her psychomotor development was severely impaired, hindered by muscular hypotonia and ataxia, both improving remarkably after CoQ10 treatment. This case suggests that there is a functional connection between the MAPK pathway and the mitochondria. This could be through the phosphorylation of a nuclear receptor essential for CoQ10 biosynthesis. Another hypothesis is that K-Ras, one of the proteins composing the MAPK pathway, might be recruited into the mitochondria to promote apoptosis. This case highlights that CoQ10 might contribute to the pathogenesis of CFC syndrome.

    Topics: Abnormalities, Multiple; Child, Preschool; Coenzymes; Craniofacial Abnormalities; Female; Heart Defects, Congenital; Humans; MAP Kinase Signaling System; Mitochondria; Mitochondrial Diseases; Muscle, Skeletal; Skin Abnormalities; Syndrome; Treatment Outcome; Ubiquinone

2007
SANDO: two novel mutations in POLG1 gene.
    Neuromuscular disorders : NMD, 2006, Volume: 16, Issue:8

    Sensory ataxia with neuropathy, dysarthria and ophthalmoparesis represent the clinical triad of SANDO, a specific mitochondrial phenotype first reported in 1997 in association with multiple mitochondrial DNA deletions and mutations in POLG1 or more rarely in the C10orf2 (twinkle-helicase) gene. We report a 44-year-old man with SANDO who harboured two novel mutations (P648R/R807C) in the POLG1 gene.

    Topics: Acetylcarnitine; Adult; Coenzymes; DNA Mutational Analysis; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Dysarthria; Hereditary Sensory and Autonomic Neuropathies; Humans; Male; Mitochondrial Myopathies; Muscle, Skeletal; Mutation; Ophthalmoplegia; Peripheral Nerves; Syndrome; Ubiquinone

2006
[A case of mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes (MELAS)--treatment with coenzyme Q10 and idebenone].
    Rinsho shinkeigaku = Clinical neurology, 1988, Volume: 28, Issue:1

    Topics: Acidosis, Lactic; Benzoquinones; Brain Diseases, Metabolic; Coenzymes; Female; Humans; Middle Aged; Mitochondria, Muscle; Neuromuscular Diseases; Quinones; Syndrome; Ubiquinone

1988
Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy.
    Journal of neurology, 1987, Volume: 234, Issue:1

    In a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes [MELAS] who had normal mitochondrial enzyme activity, high doses of coenzyme Q10 (CoQ) were administered. Clinical improvement with decreased serum lactate and pyruvate levels was observed. Though the mechanism of action of CoQ is not known, a trial is worthwhile in patients with MELAS.

    Topics: Acidosis, Lactic; Adolescent; Betamethasone; Brain Diseases; Coenzymes; Female; Humans; Mitochondria, Muscle; Muscular Diseases; Prednisolone; Syndrome; Ubiquinone

1987